NFE2L2 and metabolic dysfunction-associated steatohepatitis: These results are in good agreement with a previous study in rats in which the Nrf2 activators oltipraz and NK-252 attenuated progression of NASH-related fibrosis stimulated by a choline-deficient L-amino acid-defined diet,67 but whether or not the antifibrosis effects of oltipraz and NK-252 were mediated by Nrf2 was not addressed.